Similarly, the post-hoc analysis of the EMPA-REG OUTCOME trial revealed no significant modification effect of background RASi use on incident or worsening nephropathy (Pinteraction = 0.0578), doubling of serum creatinine, initiation of renal replacement therapy, and death from renal disease (Pinteraction = 0.6118) associated with SGLT2i therapy (6). This evidence concerns the gene MMP19 and Nephropathy.